coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
continu
spread
rapidli
across
china
march
infect
report
countri
global
date
patient
confirm
die
recent
mani
trial
design
determin
effect
therapeut
regimen
target
regimen
chloroquin
therapi
consid
sever
clinic
trial
china
shown
chloroquin
phosphat
aminoquinolin
use
malaria
treatment
effect
dose
mgday
chloroquin
phosphat
also
play
promis
role
manag
zika
viru
sarscov
outbreak
chloroquin
act
increas
ph
intracellular
vacuol
alter
protein
degrad
pathway
acid
hydrolas
lysosom
macromolecul
synthesi
endosom
posttransl
protein
modif
golgi
apparatu
macrophag
antigenpres
cell
chloroquin
interfer
antigen
process
therebi
achiev
antirheumat
respons
studi
demonstr
chloroquin
also
confer
consider
broadspectrum
antivir
correspond
author
effect
via
interf
fusion
process
virus
decreas
ph
addit
chloroquin
alter
glycosyl
cellular
receptor
coronavirus
hydroxychloroquin
fig
less
toxic
aminoquinolin
n
hydroxyethyl
side
chain
place
n
diethyl
group
chloroquin
modif
make
hydroxychloroquin
solubl
chloroquin
similar
chloroquin
hydroxychloroquin
increas
ph
confer
antivir
effect
addit
hydroxychloroquin
modul
effect
activ
immun
cell
downregul
express
tolllik
receptor
tlr
tlrmediat
signal
transduct
decreas
product
although
antimalari
activ
hydroxychloroquin
equival
chloroquin
hydroxychloroquin
prefer
chloroquin
owe
lower
ocular
toxic
retinopathi
doselimit
advers
effect
hydroxychloroquin
safe
daili
dose
appear
correspond
mgkg
ideal
bodi
weight
mgkg
actual
bodi
weight
although
clinic
data
anticoronavir
activ
chloroquin
hydroxychloroquin
agent
theoret
similar
antivir
activ
moreov
chloroquin
wide
avail
hydroxychloroquin
countri
addit
chloroquin
associ
greater
advers
effect
hydroxychloroquin
exampl
patient
chloroquin
interact
lopinavirritonavir
result
prolong
qt
interv
henc
necessari
consid
hydroxychloroquin
instead
chloroquin
latter
avail
treat
patient
exampl
iran
seriou
shortag
chloroquin
hydroxychloroquin
recommend
instead
therapeut
agent
antivir
agent
oseltamivir
lopinavirritonavir
ribavirin
etc
interferon
intraven
immunoglobulin
interfer
hydroxychloroquin
current
investig
fund
none
